Effect of Recombinant Interferon Alfa on Bone Metastases of Renal-Cell Carcinoma
- 28 February 1991
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 324 (9), 633-634
- https://doi.org/10.1056/nejm199102283240913
Abstract
Recombinant interferon alfa is the drug of choice today for routine treatment of patients with metastatic renal-cell carcinoma who are candidates for systemic therapy.1 Most responses to interferon have been observed in lung and lymph-node metastases.Keywords
This publication has 1 reference indexed in Scilit:
- Reporting results of cancer treatmentCancer, 1981